Frontier
Copyright ©The Author(s) 2021.
World J Gastroenterol. Nov 14, 2021; 27(42): 7210-7232
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7210
Table 3 Key experiments in bacteriophage for Clostridioides difficile infection treatment
Phage
Experiment
Finding
Ref.
phiCD140A single dose of phage treatment for C. difficile infection in hamstersSurviving of phage treated hamster [135]
phiCD27Phage treatment of CDI in an in vitro batch fermentation and human colon model (1) Reduction of both vegetative cell and toxin A and toxin B productions from C. difficile; and (2) No impact on others gut microbes[135]
phiCDHM1 to phiCDHM6, and phiCDHS1(1) Investigation for an effective phage combination; and (2) Phage delivered orally in hamster model every 8 h after C. difficile challenge(1) Discovery of phage-resistant colonies after a single phage treatment; and (2) Reduction of C. difficile amount and colonization using phage combination in vivo [124]
phiCDHM1, 2, 5, and 6 (1) Phage treatment before and after the biofilm formation; (2) First time using Galleria mellonella (wax moth) model for C. difficile phage; and (3) Using phage in combination with antibiotics (vancomycin)(1) Reduction and prevention of the biofilm establishment in vitro; and (2) Disease prevention in the prophylaxis group and increasing the wax moth survival rates [130]
phiCDHM1, 2, 5, and 6(1) Optimized temperate phage cocktail to treat in batch fermentation model; and (2) First metagenomic analysis of phage treatment on gut microbiome (1) C. difficile elimination after 24 h in prophylactic condition while maintain other microbiota components; and (2) No significant impact on other bacterial groups in human gut[127]
phiCDHS1 Measurement of planktonic and adhered C. difficile cells and free phage to human colon tumorigenic cell line HT-29(1) Reduction of planktonic and adhered C. difficile; and (2) No cytotoxicity to human cells[129]
phiCD24-2(1) Using engineered phage delivered Type 1-B CRISPR system as antimicrobial agent in vitro and in vivo; and (2) Mutation of phage lysogenic gene by the cI repressor and integrase gene deletion(1) C. difficile eradication effectively in engineered phage comparing with wild-type phage; and (2) Detection of lysogen due to potentially functional complements from C. difficile prophage [125]